Research programme: RNA interference-based therapeutics - RXi Pharmaceuticals

Drug Profile

Research programme: RNA interference-based therapeutics - RXi Pharmaceuticals

Alternative Names: Anti-CTFG RNAi therapy; Anti-VEGF sd-rxRNA; RXI-762; RXI-804; rxRNA®; rxRNAori®; sd-rxRNA®; Self-delivering RNAi compounds - RXi Pharmaceuticals

Latest Information Update: 05 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RXi Pharmaceuticals Corporation
  • Developer RXi Pharmaceuticals; RXi Pharmaceuticals Corporation; University of Massachusetts Medical School
  • Class Small interfering RNA; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors; PDCD 1 protein inhibitors; RNA interference; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - CNS disorders; CNS disorders; Eye disorders; Respiratory tract disorders; Retinal disorders

Highest Development Phases

  • Preclinical CNS disorders; Eye disorders; Inflammation; Non-small cell lung cancer; Respiratory tract disorders; Retinal disorders
  • Research Skin disorders
  • No development reported Metabolic disorders; Obesity; Rheumatoid arthritis
  • Discontinued Cytomegalovirus retinitis

Most Recent Events

  • 10 Aug 2017 Rxi Pharmaceuticals plans clinical trials for RXI 762 in Cancer in early 2018
  • 02 May 2016 RXi Pharmaceuticals has patent protection for sd-rxRNA® platform in Europe
  • 05 Oct 2015 RXi Pharmaceuticals receives patent allowance for its self-delivering (sd-rxRNA®) platform technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top